A 34-year-old white man developed acute rhabdomyolysis during the treatment
of scleromyxedema with interferon alfa. If interferon alfa is to be used a
s a therapeutic option for scleromyxedema the possibility of rhabdomyolysis
should be considered. To the best of our knowledge, this is the first case
in which acute rhabdomyolysis was developed during the treatment of sclero
myxedema with interferon alfa.